Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | HTR3A | P46098 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16423208 | 0.98 | CRBN (0.42) | CRBNDDB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20002700 | 0.84 | DDB1 (0.42) | CRBNDDB1HTR2CHTR6HTR1A | |
| SCHEMBL20002189 | 0.84 | DDB1 (0.42) | CRBNDDB1HTR2CHTR6HTR1A | |
| SCHEMBL642608 | 0.79 | CRBN (0.47) | CRBNDDB1GRIN1GRIN2BMAOA | |
| SCHEMBL2547361 | 0.79 | DDB1 (0.45) | CRBNDDB1HTR1AHTR3AMAOA | |
| SCHEMBL24111487 | 0.78 | CYP2A6 (0.35) | CRBNMAOAMAOB | |
| SCHEMBL28157888 | 0.78 | CRBN (0.43) | CRBNDDB1CHRNB2CHRNA4HTR6 | |
| SCHEMBL5223258 | 0.78 | DDB1 (0.43) | CRBNDDB1CHRNB2CHRNA4HTR1A | |
| Hydrochloric Acid SCHEMBL2773983 | 0.78 | DDB1 (0.44) | CRBNDDB1HTR1AHTR3AMAOA | |
| SCHEMBL15212244 | 0.77 | DDB1 (0.39) | CRBNDDB1CHRNB4CHRNA3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2832728-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | CRBN 1906/4885DDB1 3672/4885CHRNB2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.